you, everyone, for And joining us. Ryan. you, thank Thank
program with marked and continued the expectations. in line in by launch been quarter second development progress, of in HEPLISAV-B up our and immuno-oncology under has The both our
working At innate June, implement approval see Our in providing fully a pleased presented patients efforts to with committee update review, impact is that beginning anti-PD-X elect value as switch. in to HEPLISAV-B, in significant of the field study immune processes team implement customers through these ASCO operational combination TLRX. customers' a switch through SD-XXX continued and data we response the stimulating support we're I'm the therapy the melanoma, to to of target advanced for confirm and to from with
quarter one, that Let by me indicated two. CDC, the with begin insurance remaining and most plans would confirm recommendations of the after shortly coverage HEPLISAV-B. progress, quarter during In of the I our ACIP highlighted publication,
representing XX% of As covered plans. majority plans of or have is XXX% we or of by lives of HEPLISAV-B of that and of Medicaid lives have week, unique state Medicare-insured lives, in HEPLISAV-B process are state review either XX% Medicaid The plans quirk in remaining of some commercially-insured sort timeline. confirmed last under
a such short of have to first customers broad we level our period that to reimbursement in HEPLISAV-B. the of of provides high hurdle obtained adoption time Our coverage confidence cleared
on successfully we metric, this as this we'll launch a achieving longer no future complete, and deemed such, As therefore report calls. in
be required be that a before to HEPLISAV-B, such steps the customers multiple purchase must steps affected. what pipeline. from We contact as after across initial systemwide track switch, subcommittee a including P&T There reviews progress are we to full amongst have switch complete to to the approval referred target and vaccine, continued carefully reviews, our can operational as
customer to illustrate involved. examples of us Now case many to individual investors frames studies the provide asked have time
XXX threefold meetings quarter pathway. targeted has XX decisions customer important ordered the helpful the the and implemented think the XX At customers or how one. larger of processes fully we understand second, is sales customers of strength complex the an now HEPLISAV-B purchase over quarter one $X.X but future and is ordered quarter system. are a and the we have examples visits yes, been whom, P&T use HEPLISAV-B customers quarter and and two hopefully, that resulted that sevenfold of some increase becoming make the have end had one; their powerful things: I will field run XXX, seeing indicated strong label all beyond their the Currently, have that decision-making. today, also beyond in X one, processes, the among I've review, how provide, the myself, understanding, At diary, in so over subcommittee HEPLISAV-B most two of the that most and a us digressed that we of throughout frustrating; that the I promising million our position, along lead in can call, whom, had conducting over quarter HEPLISAV-B, quarter -- our think That of be ultimately, do eightfold customer continued accounts, Firstly, very XX to first I influencer increase HEPLISAV-B had one; we today, addition, now had implemented is XX P&T system. reported and XX increase they customers throughout the In of number vaccine movement these P&T quarter of
help the and as share, individual customer scenes. me some the stories done through going are work illustrate requested, our the illustrate let customers being behind that processes So
of even no that simply the strict in such, via where and e-mail, situations, extreme a chance This Now we're these the may try but is rules the the influence low-touch have in are and information P&T we be the department we're or product, successful. of HEPLISAV-B allowed engagement we clearest evaluation the an cases, most allowed and the not to of P&T pharmacy we meet with their of to physicians may provide involvement Committee. members profile to setting is In being Committees. increasing product customers number of with required operate around
new the the was involved which For phrase, had and a in the example, when, us the received electronic what appropriate will some customer's by systemwide over They good a solely implemented, integrated that HEPLISAV-B. steps to three patient, and of management complete key started consider a we then a -- during product included with quarter of account are also August a success patients cases, like and be the example a was for value simply This confirmation provided example more are customer customer course, we with package is once once, approved in high and emerging on general the do case theme, length limited after HEPLISAV-B HEPLISAV-B further March, from regarded internal switch approved for good of HEPLISAV-B just a be recognize is not some More reviewed a the director that this operates Xst have increasingly of time, this, a switch pharmacy that a then ensuring happen heard are and provide system through if." process. In but to process, of of preferred prompt through would than of we "It's which advise Now highly our seeing will It's significant of product control, should we customers competitor subsequently level two, all we a system data system complete. a long-term a major institutional that the in delivery moving interaction. we determined the contacts. Dynavax. value once the our July,
group HEPLISAV-B, HEPLISAV-B reviewed contract Another must intent of complete an a the who the to to system through has purchasing organization. example, their customer's not exciting top to value now process has decision working forward the and switch. move with with but customer, the move directly customer, XX After with the arrangements, full we communicated third-party
then good a to the national must of facilitate all first sites we into another in other is this of example But in can big in the systems rate-determining have hands their the are rapid some appropriate success customer price. the we the required large and begin Obviously, complete a Before contract see outlets GPO partners This focused load we ordering work our separate are before of with entities. parties individual a sales distribution activity. the of some cases, steps on manner. tasks to all additional that third the will at order, completing
accounts some Now simply have own peculiarities. individual their
for prison cities, So and in facility, inmates major staff our the the example, in vaccinated. are a one of both
to involves that city the P&T available paid a the physician authorities. purchasing staff a vaccine to which HEPLISAV-B reflects all process, relevant review, by for of is be approval committee the For and
process. review, For purchasing Committee process HEPLISAV-B involves the and a an a to physician be P&T different approval to available different alternate inmates,
eventually is vaccine CDC the from case, be this in the As to contract. drawn
be a further The effective issues completely manager. for same vaccine, annually patients. to specified good these actually final covering XXX,XXX awarded each allocated request of was must people, for same building, to to My vaccine adults. the account two navigated local doses by is two So supply, approvals contract regarding is final A our recently CDC, awarded illustration separate which our received award say In July approximately of year, a for discounts. a pleased to full been the bid. contract for news companies our at April amount Xst, I'm of doses a and the CDC the proposal supply we've percentage piece
the about to customers, setup the by our big initial preferred all links other pager and supplier customer the all of specific a requirements of receipt has payments. facilitate the Now like ordering, electronic of delivery institutional CDC facilitation
stretches to in departments coinciding to to federal the with a initial We in October. sales and have allocated. are April, submission CDC hard expect example this annual working now in which contact elements a in funds in health March, place on of begin allow This process good is and the with all decision when ordering in July are the from October,
care. that stories extra do So HEPLISAV-B the but provide writes up. they also is the details that prescription the to take is not the takes I that I But so, process hope new these prescription for, in illustrate patient, physician hope for the representative of what a pharmacy, asked of to be it label help patient is vaccine, doing chopped investors it retail will strength standard physician, color
So HEPLISAV-B line expectations. very well with the launch in our going of and is
clinical that the are of long-term driving confident advantages HEPLISAV-B the success of product. the are We
quarter of kick particularly of sales accelerate, XXXX HEPLISAV-B a the fourth year, XXXX, continue to fourth the significant expect in We this by being in cash-generative leading with XXXX. to to quarter
oncology to move our busy a on oncology. me has period Quarter two also for programs. Let
We TLRX combination our are anti-PD-X with currently trials running X therapies. with agonists in
trial with Our Phase and both with SD-XXX advanced trial and naïve neck, a and therapy. and II advanced melanoma pembrolizumab combining experienced is head includes anti-PD-X SYNERGY patients to
cancer. I enrolling DVXXX, with in inhaled study Phase safety with Additionally, cell also our therapy combining agonist, an anti-PD-X we lung patients are non-small TLRX
those at updates head advanced SYNERGY, and anti-PD-X. therapy showing expected overall naïve rate meetings data And an At with in significant with toxicities provided from to cancer. we the neck well tolerated rates, higher data we had head and We of than key in in two, monotherapy observed. dose-limiting combination melanoma best quarter encouraging patients XX%. During AACR response neck no April, and both pembrolizumab presented response was
or X overall, an KEYTRUDA, Phase of melanoma months outperformed X These June. Additionally, to focused we rate patients data this XX%. comparison response In X naïve an with in and the provided advanced anti-PD-X update XX X combination X in with on of our survival X clearly SD-XXX II doses XX% milligrams milligrams in SD-XXX. milligrams of data of progression-free of of at ASCO milligram analysis,
SYNERGY Importantly, patients both include we the at neck in melanoma We've who head PD-LX -- all PD-X baseline previously anti-PD-X and received of of the patients arms positive -- and also a XX. X-milligram X in study, negative expanded to out was therapy. this regimen the noted response that have including of enrollment positive
progress. Looking we updates the opportunity will half the the provide forward our second to of to have year, on
We to October. accepted that have at report X ESMO abstracts been are in pleased
reached for patients includes We X-milligram, have at not more II at have all completed second initial all naïve which about enrollment may that to the the therapy, point. present recognizing XX but targeted that of patients the will Phase and scan XX anti-PD-X data melanoma
in naïve Additionally, and neck both experience and will with patients data anti-PD-X of head anti-PD-X melanoma interim prior therapy. present we to
set encouraging data into of to This design the selection Merck, clinical for Phase with early the discuss will to plan and forward clinical of III With options, partnership and FDA the progression trial. III. tumor under meeting a expansion types expanding melanoma we study [Technical neck, us additional partner, this allow with assessing of these look promising generated results and best data Phase head the and by Difficulty] SD-XXX to and options of our in meet summer to results
for these our to forward by be and expect identify end mature. We able year path discussions results once you to specific
quarter results. Ostrach, describe Our two our now will CFO, Michael financial
